Technical Analysis for CYTK - Cytokinetics, Incorporated

Grade Last Price % Change Price Change
grade A 8.75 -1.02% -0.09
CYTK closed down 1.02 percent on Friday, March 22, 2019, on 86 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical CYTK trend table...

Date Alert Name Type % Chg
Mar 22 Calm After Storm Range Contraction 0.00%
Mar 22 Upper Bollinger Band Walk Strength 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 21 Slingshot Bullish Bullish Swing Setup -1.02%
Mar 21 Volume Surge Other -1.02%
Mar 21 Wide Range Bar Range Expansion -1.02%
Mar 21 Upper Bollinger Band Walk Strength -1.02%
Mar 21 Multiple of Ten Bearish Other -1.02%
Mar 21 Wide Bands Range Expansion -1.02%

Older signals for CYTK ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment, in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Biopharmaceutical Diseases Disease Neuroscience Serious Diseases Anatomy Heart Failure Amyotrophic Lateral Sclerosis Nervous System Astellas Pharma Treatment Of Heart Failure Treatment Of Serious Diseases
Is CYTK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 10.44
52 Week Low 5.75
Average Volume 548,555
200-Day Moving Average 7.6513
50-Day Moving Average 7.2658
20-Day Moving Average 7.3935
10-Day Moving Average 8.03
Average True Range 0.5734
ADX 30.12
+DI 43.9483
-DI 12.2927
Chandelier Exit (Long, 3 ATRs ) 8.7198
Chandelier Exit (Short, 3 ATRs ) 7.4702
Upper Bollinger Band 9.4835
Lower Bollinger Band 5.3035
Percent B (%b) 0.82
BandWidth 56.536147
MACD Line 0.4755
MACD Signal Line 0.2095
MACD Histogram 0.266
Fundamentals Value
Market Cap 469.58 Million
Num Shares 53.7 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -25.74
Price-to-Sales 6.91
Price-to-Book 3.91
PEG Ratio -0.34
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.55
Resistance 3 (R3) 9.62 9.43 9.41
Resistance 2 (R2) 9.43 9.23 9.39 9.37
Resistance 1 (R1) 9.09 9.10 9.00 9.02 9.32
Pivot Point 8.90 8.90 8.85 8.86 8.90
Support 1 (S1) 8.56 8.70 8.47 8.49 8.18
Support 2 (S2) 8.37 8.57 8.33 8.13
Support 3 (S3) 8.03 8.37 8.09
Support 4 (S4) 7.96